Sepsis is a leading cause of death. It is also a major driver of antibiotic utilization, in large part because current guidelines and mandates compel clinicians to administer antibiotics immediately for all patients with possible sepsis even though more than a third of patients initially suspected to have sepsis turn out to have viral or non-infectious conditions. The Centers for Medicare & Medicaid Services (CMS) ?SEP-1? measure, for example, requires hospitals to give broad-spectrum antibiotics within 3 hours of to all patients with suspected sepsis as well as measure lactate levels, draw blood cultures, and administer at least 30cc/kg of fluids for hypotension. Newer guidelines are pushing for even faster antibiotic administration and bundle completion. Aggressive, rigid, and reflexive sepsis care may therefore benefit some patients but also unnecessarily risks promoting antibiotic resistance, drug adverse events, C.difficile infections, and fluid overload in others. A major barrier to providing appropriate sepsis care to the right patients is our limited understanding of which specific clinical presentations are most likely to benefit from immediate antibiotics and which can safely be managed more conservatively. Similarly, we have imperfect understanding of which specific processes of care are critical to optimize outcomes and which are not. To address these gaps, we need a better way to define sepsis ?time zero,? a concept that embodies both the criteria that should trigger immediate interventions when infection is suspected and the point from which timeliness of care is measured. The current definition of sepsis includes a heterogeneous mix of clinical signs, some of which are clearly urgent and some that may tolerate more time for investigation before administering antibiotics. The problem is compounded by the fact that SEP-1's time zero definition is subjective and labor-intensive to abstract, undermining its credibility and utility for benchmarking hospitals' quality of care. In this project, we propose to leverage detailed electronic health record data from millions of encounters from 167 hospitals in two datasets to develop more evidence-based sepsis time zero criteria and quality metrics. These goals are reflected our Specific Aims: 1) Develop evidence-based, objective, and electronically computable definitions of sepsis time zero by using electronic health record data to identify the clinical signs that are associated with higher mortality when antibiotics are delayed, 2) Systematically evaluate the associations between each sepsis bundle component and mortality and compare the full bundle to simpler, streamlined versions, and 3) Assess whether and how optimal treatment strategies differ for commonly encountered and easily recognizable sepsis phenotypes based on infection site, comorbidities, and clinical signs. This proposal directly addresses the antibiotic stewardship focus of AHRQ's HAI Prevention Portfolio and AHRQ's mission to improve health care safety and quality by providing new insights into identifying and treating sepsis, informing more rational antibiotic use, and facilitating better measurement of quality-of-care. 1
Current sepsis guidelines and national quality measures strongly encourage clinicians to administer immediate broad-spectrum antibiotics and bundled care to all patients with suspected sepsis even though more than a third turn out to have non-infectious diagnoses. A major obstacle for clinicians, hospitals, and policy makers is a limited understanding of which clinical presentations truly require immediate antibiotics and which processes of care are most important to optimizing patients' outcomes. In this project, we will leverage detailed electronic health record data from millions of encounters from two large healthcare networks to 1) develop evidence- based, objective, and electronically computable definitions of sepsis ?time zero? that can be used to identify which patients with possible infection require immediate antibiotics, while also facilitating efficient monitoring of sepsis care, 2) systematically evaluate the associations between each sepsis bundle component and mortality and compare the full bundle to simpler, streamlined versions, and 3) assess whether and how optimal treatment strategies differ for commonly encountered and easily recognizable sepsis phenotypes. 1
